Markers of endocrine sensitivity

Breast Cancer Research

Volumn 10, Issue SUPPL. 4, 2008, Pages

  Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 60749110936     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2178     Document Type: Article

References (27)

1. Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1896, 148:104-107.
2. De Sombre ER, Puca GA, Jensen EV. Purification of an estrophilic protein from calf uterus. Proc Natl Acad Sci USA 1969, 64:148-154. 286139, 5262996, 10.1073/pnas.64.1.148.
3. McGuire WL. Estrogen receptors in human breast cancer. J Clin Invest 1973, 52:73-77. 302228, 4345203, 10.1172/JCI107175.
4. McGuire W, Carbone PP, Sears ME, et al. Estrogen receptors in human breast cancer. Estrogen Receptors in Human Breast Cancer 1975, 1-7. New York City, NY: Raven Press, McGuire WL, Carbone PP, Vollmer EP.
5. Osborne CK, McGuire WL. Current use of steroid hormone receptor assays in the treatment of breast cancer. Surg Clin North Am 1978, 58:777-788.
6. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group.
7. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
8. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M, Wheeler TM, Hayes DF, . American Society of Clinical Oncology; College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. 10.1200/JCO.2006.09.2775, 17159189, American Society of Clinical Oncology; College of American Pathologists.
9. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
10. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980, 46(suppl):2884-2888.
11. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992, 10:1284-1291.
12. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, . BIG 1-98 Collaborative and International Breast Cancer Study Groups Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for post-menopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008, 9:23-28. 10.1016/S1470-2045(07)70386-8, 18083065, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
13. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group. J Clin Oncol 2008, 26:1404-1410. 10.1200/JCO.2007.10.6393, 18349391.
14. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008, 26:1059-1065. 10.1200/JCO.2007.12.9437, 18227529.
15. Van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005, 23:1631-1635. 10.1200/JCO.2005.12.005, 15755970.
16. Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 2006, 12:2080-2087. 10.1158/1078-0432.CCR-05-1263, 16609019.
17. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
18. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35-42. 1602211, 14695316.
19. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734. 10.1200/JCO.2005.04.7985, 16720680.
20. Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh IT, Ravdin P, Yoshizawa C, Baehner FL, Davidson N, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-poisitive breast cancer (S INT0100). Breast Cancer Res Treat 8814, 106(suppl 1). late breaking abstract, #10..
21. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
22. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
23. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006, 80:61-74. 10.1016/j.clpt.2006.03.013, 16815318.
24. Hayes DF, Stearns V, Rae J, Flockhart D. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?. J Natl Cancer Inst 2008, 100:610-613. 10.1093/jnci/djn127, 18445818.
25. Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, Li L, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA, Hayes DF, . Consortium on Breast Cancer Pharmacogenomics Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther 2008, 83:702-710. 10.1038/sj.clpt.6100343, 17713466, Consortium on Breast Cancer Pharmacogenomics.
26. Henry NL, Nguyen A, Azzouz F, Li L, Robarge J, Philips S, Cao D, Skaar T, Storniolo AM, Flockhart DA, et al. Association of estrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. J Clin Oncol 2008,
27. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Muñoz M, Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras B, Alba E. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008, 14:811-816. 10.1158/1078-0432.CCR-07-1923, 18245543.